nodes	percent_of_prediction	percent_of_DWPC	metapath
Bismuth Subsalicylate—PTGS2—pancreatic cancer	0.559	1	CbGaD
Bismuth Subsalicylate—ALB—Erlotinib—pancreatic cancer	0.0642	0.361	CbGbCtD
Bismuth Subsalicylate—ALB—Irinotecan—pancreatic cancer	0.058	0.326	CbGbCtD
Bismuth Subsalicylate—ALB—Fluorouracil—pancreatic cancer	0.0556	0.313	CbGbCtD
Bismuth Subsalicylate—TF—bile—pancreatic cancer	0.0333	0.529	CbGeAlD
Bismuth Subsalicylate—TF—gall bladder—pancreatic cancer	0.00925	0.147	CbGeAlD
Bismuth Subsalicylate—ALB—gall bladder—pancreatic cancer	0.00481	0.0765	CbGeAlD
Bismuth Subsalicylate—TF—pancreas—pancreatic cancer	0.00426	0.0677	CbGeAlD
Bismuth Subsalicylate—TF—digestive system—pancreatic cancer	0.00364	0.0578	CbGeAlD
Bismuth Subsalicylate—PTGS2—gall bladder—pancreatic cancer	0.00262	0.0417	CbGeAlD
Bismuth Subsalicylate—PTGS2—islet of Langerhans—pancreatic cancer	0.00172	0.0273	CbGeAlD
Bismuth Subsalicylate—Hearing impaired—Gemcitabine—pancreatic cancer	0.00133	0.00958	CcSEcCtD
Bismuth Subsalicylate—Heartburn—Docetaxel—pancreatic cancer	0.0013	0.0094	CcSEcCtD
Bismuth Subsalicylate—Burning sensation—Docetaxel—pancreatic cancer	0.00129	0.00931	CcSEcCtD
Bismuth Subsalicylate—PTGS2—pancreas—pancreatic cancer	0.00121	0.0192	CbGeAlD
Bismuth Subsalicylate—Skin exfoliation—Gemcitabine—pancreatic cancer	0.0012	0.00871	CcSEcCtD
Bismuth Subsalicylate—Hyponatraemia—Sunitinib—pancreatic cancer	0.00115	0.00828	CcSEcCtD
Bismuth Subsalicylate—Oesophagitis—Fluorouracil—pancreatic cancer	0.00113	0.00819	CcSEcCtD
Bismuth Subsalicylate—Venous thrombosis—Epirubicin—pancreatic cancer	0.00112	0.00809	CcSEcCtD
Bismuth Subsalicylate—Abdominal discomfort—Tamoxifen—pancreatic cancer	0.0011	0.00798	CcSEcCtD
Bismuth Subsalicylate—PTGS1—digestive system—pancreatic cancer	0.00108	0.0171	CbGeAlD
Bismuth Subsalicylate—Weight increased—Tamoxifen—pancreatic cancer	0.00105	0.00758	CcSEcCtD
Bismuth Subsalicylate—Abdominal pain upper—Sunitinib—pancreatic cancer	0.00104	0.00753	CcSEcCtD
Bismuth Subsalicylate—Gastric ulcer—Epirubicin—pancreatic cancer	0.00104	0.00751	CcSEcCtD
Bismuth Subsalicylate—Venous thrombosis—Doxorubicin—pancreatic cancer	0.00104	0.00748	CcSEcCtD
Bismuth Subsalicylate—PTGS2—digestive system—pancreatic cancer	0.00103	0.0164	CbGeAlD
Bismuth Subsalicylate—Extravasation—Docetaxel—pancreatic cancer	0.00103	0.00742	CcSEcCtD
Bismuth Subsalicylate—Deafness—Gemcitabine—pancreatic cancer	0.00102	0.0074	CcSEcCtD
Bismuth Subsalicylate—Gastric ulcer—Doxorubicin—pancreatic cancer	0.000962	0.00695	CcSEcCtD
Bismuth Subsalicylate—Epistaxis—Erlotinib—pancreatic cancer	0.000958	0.00693	CcSEcCtD
Bismuth Subsalicylate—Abdominal discomfort—Sunitinib—pancreatic cancer	0.000946	0.00684	CcSEcCtD
Bismuth Subsalicylate—Hyponatraemia—Irinotecan—pancreatic cancer	0.000944	0.00682	CcSEcCtD
Bismuth Subsalicylate—Hearing impaired—Docetaxel—pancreatic cancer	0.000941	0.0068	CcSEcCtD
Bismuth Subsalicylate—Hepatitis—Tamoxifen—pancreatic cancer	0.000922	0.00666	CcSEcCtD
Bismuth Subsalicylate—Lethargy—Fluorouracil—pancreatic cancer	0.000919	0.00664	CcSEcCtD
Bismuth Subsalicylate—Hepatitis—Erlotinib—pancreatic cancer	0.000912	0.00659	CcSEcCtD
Bismuth Subsalicylate—Erythema multiforme—Tamoxifen—pancreatic cancer	0.000872	0.0063	CcSEcCtD
Bismuth Subsalicylate—Burning sensation—Epirubicin—pancreatic cancer	0.000869	0.00628	CcSEcCtD
Bismuth Subsalicylate—Erythema multiforme—Erlotinib—pancreatic cancer	0.000863	0.00623	CcSEcCtD
Bismuth Subsalicylate—Skin exfoliation—Docetaxel—pancreatic cancer	0.000855	0.00618	CcSEcCtD
Bismuth Subsalicylate—Lung disorder—Epirubicin—pancreatic cancer	0.000853	0.00617	CcSEcCtD
Bismuth Subsalicylate—Epistaxis—Sunitinib—pancreatic cancer	0.00083	0.006	CcSEcCtD
Bismuth Subsalicylate—Oesophagitis—Docetaxel—pancreatic cancer	0.000818	0.00591	CcSEcCtD
Bismuth Subsalicylate—Burning sensation—Doxorubicin—pancreatic cancer	0.000804	0.00581	CcSEcCtD
Bismuth Subsalicylate—Erythema—Tamoxifen—pancreatic cancer	0.000803	0.0058	CcSEcCtD
Bismuth Subsalicylate—Lightheadedness—Docetaxel—pancreatic cancer	0.000801	0.00579	CcSEcCtD
Bismuth Subsalicylate—Erythema—Erlotinib—pancreatic cancer	0.000794	0.00574	CcSEcCtD
Bismuth Subsalicylate—Hepatitis—Sunitinib—pancreatic cancer	0.00079	0.00571	CcSEcCtD
Bismuth Subsalicylate—Lung disorder—Doxorubicin—pancreatic cancer	0.00079	0.00571	CcSEcCtD
Bismuth Subsalicylate—Dysgeusia—Tamoxifen—pancreatic cancer	0.000786	0.00568	CcSEcCtD
Bismuth Subsalicylate—Phlebitis—Docetaxel—pancreatic cancer	0.000754	0.00545	CcSEcCtD
Bismuth Subsalicylate—Erythema multiforme—Sunitinib—pancreatic cancer	0.000747	0.0054	CcSEcCtD
Bismuth Subsalicylate—Stinging—Epirubicin—pancreatic cancer	0.000745	0.00539	CcSEcCtD
Bismuth Subsalicylate—Deafness—Docetaxel—pancreatic cancer	0.000727	0.00525	CcSEcCtD
Bismuth Subsalicylate—Extravasation—Epirubicin—pancreatic cancer	0.000692	0.005	CcSEcCtD
Bismuth Subsalicylate—Stinging—Doxorubicin—pancreatic cancer	0.00069	0.00498	CcSEcCtD
Bismuth Subsalicylate—Erythema—Sunitinib—pancreatic cancer	0.000687	0.00497	CcSEcCtD
Bismuth Subsalicylate—Dysgeusia—Sunitinib—pancreatic cancer	0.000673	0.00486	CcSEcCtD
Bismuth Subsalicylate—Lethargy—Docetaxel—pancreatic cancer	0.000663	0.00479	CcSEcCtD
Bismuth Subsalicylate—Oedema—Tamoxifen—pancreatic cancer	0.000655	0.00473	CcSEcCtD
Bismuth Subsalicylate—Epistaxis—Fluorouracil—pancreatic cancer	0.000655	0.00473	CcSEcCtD
Bismuth Subsalicylate—Hyponatraemia—Docetaxel—pancreatic cancer	0.000653	0.00472	CcSEcCtD
Bismuth Subsalicylate—Infection—Tamoxifen—pancreatic cancer	0.000651	0.0047	CcSEcCtD
Bismuth Subsalicylate—Oedema—Erlotinib—pancreatic cancer	0.000648	0.00468	CcSEcCtD
Bismuth Subsalicylate—Infection—Erlotinib—pancreatic cancer	0.000644	0.00465	CcSEcCtD
Bismuth Subsalicylate—Extravasation—Doxorubicin—pancreatic cancer	0.000641	0.00463	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Tamoxifen—pancreatic cancer	0.000624	0.00451	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Erlotinib—pancreatic cancer	0.000618	0.00446	CcSEcCtD
Bismuth Subsalicylate—Erythema multiforme—Gemcitabine—pancreatic cancer	0.000599	0.00433	CcSEcCtD
Bismuth Subsalicylate—Abdominal pain upper—Docetaxel—pancreatic cancer	0.000594	0.00429	CcSEcCtD
Bismuth Subsalicylate—Skin exfoliation—Epirubicin—pancreatic cancer	0.000577	0.00417	CcSEcCtD
Bismuth Subsalicylate—Dyspepsia—Tamoxifen—pancreatic cancer	0.000577	0.00417	CcSEcCtD
Bismuth Subsalicylate—Dyspepsia—Erlotinib—pancreatic cancer	0.00057	0.00412	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Tamoxifen—pancreatic cancer	0.000569	0.00412	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Erlotinib—pancreatic cancer	0.000563	0.00407	CcSEcCtD
Bismuth Subsalicylate—Oedema—Sunitinib—pancreatic cancer	0.000561	0.00405	CcSEcCtD
Bismuth Subsalicylate—Pain—Tamoxifen—pancreatic cancer	0.00056	0.00405	CcSEcCtD
Bismuth Subsalicylate—Constipation—Tamoxifen—pancreatic cancer	0.00056	0.00405	CcSEcCtD
Bismuth Subsalicylate—Infection—Sunitinib—pancreatic cancer	0.000557	0.00403	CcSEcCtD
Bismuth Subsalicylate—Pain—Erlotinib—pancreatic cancer	0.000554	0.00401	CcSEcCtD
Bismuth Subsalicylate—Constipation—Erlotinib—pancreatic cancer	0.000554	0.00401	CcSEcCtD
Bismuth Subsalicylate—Oesophagitis—Epirubicin—pancreatic cancer	0.000552	0.00399	CcSEcCtD
Bismuth Subsalicylate—Erythema—Gemcitabine—pancreatic cancer	0.000552	0.00399	CcSEcCtD
Bismuth Subsalicylate—Ecchymosis—Epirubicin—pancreatic cancer	0.000546	0.00395	CcSEcCtD
Bismuth Subsalicylate—Erythema—Fluorouracil—pancreatic cancer	0.000542	0.00392	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Sunitinib—pancreatic cancer	0.000535	0.00386	CcSEcCtD
Bismuth Subsalicylate—Skin exfoliation—Doxorubicin—pancreatic cancer	0.000534	0.00386	CcSEcCtD
Bismuth Subsalicylate—Urticaria—Tamoxifen—pancreatic cancer	0.00052	0.00376	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Erlotinib—pancreatic cancer	0.000512	0.0037	CcSEcCtD
Bismuth Subsalicylate—Weight increased—Docetaxel—pancreatic cancer	0.000511	0.00369	CcSEcCtD
Bismuth Subsalicylate—Oesophagitis—Doxorubicin—pancreatic cancer	0.000511	0.00369	CcSEcCtD
Bismuth Subsalicylate—Phlebitis—Epirubicin—pancreatic cancer	0.000509	0.00368	CcSEcCtD
Bismuth Subsalicylate—Ecchymosis—Doxorubicin—pancreatic cancer	0.000505	0.00365	CcSEcCtD
Bismuth Subsalicylate—Dyspepsia—Sunitinib—pancreatic cancer	0.000494	0.00357	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Sunitinib—pancreatic cancer	0.000488	0.00352	CcSEcCtD
Bismuth Subsalicylate—Constipation—Sunitinib—pancreatic cancer	0.00048	0.00347	CcSEcCtD
Bismuth Subsalicylate—Pain—Sunitinib—pancreatic cancer	0.00048	0.00347	CcSEcCtD
Bismuth Subsalicylate—Epistaxis—Docetaxel—pancreatic cancer	0.000472	0.00341	CcSEcCtD
Bismuth Subsalicylate—Phlebitis—Doxorubicin—pancreatic cancer	0.000471	0.0034	CcSEcCtD
Bismuth Subsalicylate—Confusional state—Irinotecan—pancreatic cancer	0.000466	0.00337	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Tamoxifen—pancreatic cancer	0.000463	0.00335	CcSEcCtD
Bismuth Subsalicylate—Oedema—Irinotecan—pancreatic cancer	0.000462	0.00334	CcSEcCtD
Bismuth Subsalicylate—Infection—Irinotecan—pancreatic cancer	0.000459	0.00332	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Erlotinib—pancreatic cancer	0.000459	0.00331	CcSEcCtD
Bismuth Subsalicylate—Oedema—Gemcitabine—pancreatic cancer	0.00045	0.00325	CcSEcCtD
Bismuth Subsalicylate—Hepatitis—Docetaxel—pancreatic cancer	0.00045	0.00325	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Tamoxifen—pancreatic cancer	0.000448	0.00324	CcSEcCtD
Bismuth Subsalicylate—Lethargy—Epirubicin—pancreatic cancer	0.000447	0.00323	CcSEcCtD
Bismuth Subsalicylate—Infection—Gemcitabine—pancreatic cancer	0.000447	0.00323	CcSEcCtD
Bismuth Subsalicylate—Confusional state—Fluorouracil—pancreatic cancer	0.000446	0.00323	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Sunitinib—pancreatic cancer	0.000444	0.00321	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Erlotinib—pancreatic cancer	0.000443	0.0032	CcSEcCtD
Bismuth Subsalicylate—Oedema—Fluorouracil—pancreatic cancer	0.000443	0.0032	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Irinotecan—pancreatic cancer	0.000441	0.00318	CcSEcCtD
Bismuth Subsalicylate—Hyponatraemia—Epirubicin—pancreatic cancer	0.00044	0.00318	CcSEcCtD
Bismuth Subsalicylate—Infection—Fluorouracil—pancreatic cancer	0.00044	0.00318	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Tamoxifen—pancreatic cancer	0.000433	0.00313	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Gemcitabine—pancreatic cancer	0.000429	0.0031	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Erlotinib—pancreatic cancer	0.000429	0.0031	CcSEcCtD
Bismuth Subsalicylate—Erythema multiforme—Docetaxel—pancreatic cancer	0.000425	0.00307	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Fluorouracil—pancreatic cancer	0.000422	0.00305	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Tamoxifen—pancreatic cancer	0.000416	0.00301	CcSEcCtD
Bismuth Subsalicylate—Lethargy—Doxorubicin—pancreatic cancer	0.000414	0.00299	CcSEcCtD
Bismuth Subsalicylate—Rash—Tamoxifen—pancreatic cancer	0.000413	0.00298	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Tamoxifen—pancreatic cancer	0.000413	0.00298	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Erlotinib—pancreatic cancer	0.000412	0.00298	CcSEcCtD
Bismuth Subsalicylate—Somnolence—Irinotecan—pancreatic cancer	0.000411	0.00297	CcSEcCtD
Bismuth Subsalicylate—Headache—Tamoxifen—pancreatic cancer	0.00041	0.00297	CcSEcCtD
Bismuth Subsalicylate—Rash—Erlotinib—pancreatic cancer	0.000409	0.00295	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Erlotinib—pancreatic cancer	0.000408	0.00295	CcSEcCtD
Bismuth Subsalicylate—Hyponatraemia—Doxorubicin—pancreatic cancer	0.000407	0.00294	CcSEcCtD
Bismuth Subsalicylate—Dyspepsia—Irinotecan—pancreatic cancer	0.000407	0.00294	CcSEcCtD
Bismuth Subsalicylate—Headache—Erlotinib—pancreatic cancer	0.000406	0.00293	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Irinotecan—pancreatic cancer	0.000402	0.0029	CcSEcCtD
Bismuth Subsalicylate—Abdominal pain upper—Epirubicin—pancreatic cancer	0.0004	0.00289	CcSEcCtD
Bismuth Subsalicylate—Somnolence—Gemcitabine—pancreatic cancer	0.0004	0.00289	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Sunitinib—pancreatic cancer	0.000397	0.00287	CcSEcCtD
Bismuth Subsalicylate—Pain—Irinotecan—pancreatic cancer	0.000395	0.00286	CcSEcCtD
Bismuth Subsalicylate—Constipation—Irinotecan—pancreatic cancer	0.000395	0.00286	CcSEcCtD
Bismuth Subsalicylate—Somnolence—Fluorouracil—pancreatic cancer	0.000393	0.00284	CcSEcCtD
Bismuth Subsalicylate—Erythema—Docetaxel—pancreatic cancer	0.000391	0.00283	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Gemcitabine—pancreatic cancer	0.000391	0.00283	CcSEcCtD
Bismuth Subsalicylate—Dyspepsia—Fluorouracil—pancreatic cancer	0.00039	0.00282	CcSEcCtD
Bismuth Subsalicylate—Nausea—Tamoxifen—pancreatic cancer	0.000389	0.00281	CcSEcCtD
Bismuth Subsalicylate—Constipation—Gemcitabine—pancreatic cancer	0.000385	0.00278	CcSEcCtD
Bismuth Subsalicylate—Pain—Gemcitabine—pancreatic cancer	0.000385	0.00278	CcSEcCtD
Bismuth Subsalicylate—Nausea—Erlotinib—pancreatic cancer	0.000385	0.00278	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Fluorouracil—pancreatic cancer	0.000385	0.00278	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Sunitinib—pancreatic cancer	0.000384	0.00277	CcSEcCtD
Bismuth Subsalicylate—Dysgeusia—Docetaxel—pancreatic cancer	0.000383	0.00277	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Irinotecan—pancreatic cancer	0.000381	0.00275	CcSEcCtD
Bismuth Subsalicylate—Asthma—Epirubicin—pancreatic cancer	0.000379	0.00274	CcSEcCtD
Bismuth Subsalicylate—Pain—Fluorouracil—pancreatic cancer	0.000379	0.00274	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Sunitinib—pancreatic cancer	0.000371	0.00268	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Gemcitabine—pancreatic cancer	0.000371	0.00268	CcSEcCtD
Bismuth Subsalicylate—Abdominal pain upper—Doxorubicin—pancreatic cancer	0.00037	0.00268	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Irinotecan—pancreatic cancer	0.000365	0.00264	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Fluorouracil—pancreatic cancer	0.000365	0.00264	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Sunitinib—pancreatic cancer	0.000357	0.00258	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Gemcitabine—pancreatic cancer	0.000356	0.00257	CcSEcCtD
Bismuth Subsalicylate—Rash—Sunitinib—pancreatic cancer	0.000354	0.00256	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Sunitinib—pancreatic cancer	0.000353	0.00255	CcSEcCtD
Bismuth Subsalicylate—Urticaria—Fluorouracil—pancreatic cancer	0.000352	0.00254	CcSEcCtD
Bismuth Subsalicylate—Headache—Sunitinib—pancreatic cancer	0.000351	0.00254	CcSEcCtD
Bismuth Subsalicylate—Asthma—Doxorubicin—pancreatic cancer	0.000351	0.00253	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Fluorouracil—pancreatic cancer	0.00035	0.00253	CcSEcCtD
Bismuth Subsalicylate—Weight increased—Epirubicin—pancreatic cancer	0.000345	0.00249	CcSEcCtD
Bismuth Subsalicylate—Drowsiness—Epirubicin—pancreatic cancer	0.000338	0.00244	CcSEcCtD
Bismuth Subsalicylate—Nausea—Sunitinib—pancreatic cancer	0.000333	0.00241	CcSEcCtD
Bismuth Subsalicylate—Confusional state—Docetaxel—pancreatic cancer	0.000322	0.00233	CcSEcCtD
Bismuth Subsalicylate—Oedema—Docetaxel—pancreatic cancer	0.000319	0.00231	CcSEcCtD
Bismuth Subsalicylate—Weight increased—Doxorubicin—pancreatic cancer	0.000319	0.00231	CcSEcCtD
Bismuth Subsalicylate—Epistaxis—Epirubicin—pancreatic cancer	0.000319	0.0023	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Gemcitabine—pancreatic cancer	0.000318	0.0023	CcSEcCtD
Bismuth Subsalicylate—Infection—Docetaxel—pancreatic cancer	0.000317	0.00229	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Irinotecan—pancreatic cancer	0.000316	0.00229	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Fluorouracil—pancreatic cancer	0.000313	0.00226	CcSEcCtD
Bismuth Subsalicylate—Drowsiness—Doxorubicin—pancreatic cancer	0.000313	0.00226	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Gemcitabine—pancreatic cancer	0.000308	0.00223	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Irinotecan—pancreatic cancer	0.000306	0.00221	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Docetaxel—pancreatic cancer	0.000305	0.0022	CcSEcCtD
Bismuth Subsalicylate—Hepatitis—Epirubicin—pancreatic cancer	0.000303	0.00219	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Fluorouracil—pancreatic cancer	0.000303	0.00219	CcSEcCtD
Bismuth Subsalicylate—Epistaxis—Doxorubicin—pancreatic cancer	0.000295	0.00213	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Irinotecan—pancreatic cancer	0.000294	0.00212	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Fluorouracil—pancreatic cancer	0.000293	0.00212	CcSEcCtD
Bismuth Subsalicylate—Rash—Irinotecan—pancreatic cancer	0.000291	0.00211	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Irinotecan—pancreatic cancer	0.000291	0.0021	CcSEcCtD
Bismuth Subsalicylate—Headache—Irinotecan—pancreatic cancer	0.00029	0.00209	CcSEcCtD
Bismuth Subsalicylate—Erythema multiforme—Epirubicin—pancreatic cancer	0.000287	0.00207	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Gemcitabine—pancreatic cancer	0.000286	0.00207	CcSEcCtD
Bismuth Subsalicylate—Somnolence—Docetaxel—pancreatic cancer	0.000284	0.00205	CcSEcCtD
Bismuth Subsalicylate—Rash—Gemcitabine—pancreatic cancer	0.000284	0.00205	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Gemcitabine—pancreatic cancer	0.000284	0.00205	CcSEcCtD
Bismuth Subsalicylate—Tinnitus—Epirubicin—pancreatic cancer	0.000283	0.00204	CcSEcCtD
Bismuth Subsalicylate—Headache—Gemcitabine—pancreatic cancer	0.000282	0.00204	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Fluorouracil—pancreatic cancer	0.000281	0.00203	CcSEcCtD
Bismuth Subsalicylate—Dyspepsia—Docetaxel—pancreatic cancer	0.000281	0.00203	CcSEcCtD
Bismuth Subsalicylate—Hepatitis—Doxorubicin—pancreatic cancer	0.000281	0.00203	CcSEcCtD
Bismuth Subsalicylate—Rash—Fluorouracil—pancreatic cancer	0.000279	0.00202	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Fluorouracil—pancreatic cancer	0.000279	0.00201	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Docetaxel—pancreatic cancer	0.000278	0.00201	CcSEcCtD
Bismuth Subsalicylate—Headache—Fluorouracil—pancreatic cancer	0.000277	0.002	CcSEcCtD
Bismuth Subsalicylate—Nausea—Irinotecan—pancreatic cancer	0.000275	0.00198	CcSEcCtD
Bismuth Subsalicylate—Pain—Docetaxel—pancreatic cancer	0.000273	0.00197	CcSEcCtD
Bismuth Subsalicylate—Constipation—Docetaxel—pancreatic cancer	0.000273	0.00197	CcSEcCtD
Bismuth Subsalicylate—Nausea—Gemcitabine—pancreatic cancer	0.000267	0.00193	CcSEcCtD
Bismuth Subsalicylate—Erythema multiforme—Doxorubicin—pancreatic cancer	0.000265	0.00192	CcSEcCtD
Bismuth Subsalicylate—Erythema—Epirubicin—pancreatic cancer	0.000264	0.00191	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Docetaxel—pancreatic cancer	0.000263	0.0019	CcSEcCtD
Bismuth Subsalicylate—Nausea—Fluorouracil—pancreatic cancer	0.000263	0.0019	CcSEcCtD
Bismuth Subsalicylate—Tinnitus—Doxorubicin—pancreatic cancer	0.000262	0.00189	CcSEcCtD
Bismuth Subsalicylate—Dysgeusia—Epirubicin—pancreatic cancer	0.000259	0.00187	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Docetaxel—pancreatic cancer	0.000253	0.00183	CcSEcCtD
Bismuth Subsalicylate—TF—SIDS Susceptibility Pathways—VEGFA—pancreatic cancer	0.000247	0.00398	CbGpPWpGaD
Bismuth Subsalicylate—Erythema—Doxorubicin—pancreatic cancer	0.000244	0.00177	CcSEcCtD
Bismuth Subsalicylate—ALB—Binding and Uptake of Ligands by Scavenger Receptors—APOE—pancreatic cancer	0.000242	0.00391	CbGpPWpGaD
Bismuth Subsalicylate—Dysgeusia—Doxorubicin—pancreatic cancer	0.000239	0.00173	CcSEcCtD
Bismuth Subsalicylate—TF—Platelet activation, signaling and aggregation—PIK3CB—pancreatic cancer	0.000239	0.00386	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Aryl Hydrocarbon Receptor—RB1—pancreatic cancer	0.000228	0.00367	CbGpPWpGaD
Bismuth Subsalicylate—Pruritus—Docetaxel—pancreatic cancer	0.000226	0.00163	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PPARG—pancreatic cancer	0.000223	0.00359	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Arachidonic acid metabolism—PTGS2—pancreatic cancer	0.000221	0.00356	CbGpPWpGaD
Bismuth Subsalicylate—Diarrhoea—Docetaxel—pancreatic cancer	0.000219	0.00158	CcSEcCtD
Bismuth Subsalicylate—Confusional state—Epirubicin—pancreatic cancer	0.000217	0.00157	CcSEcCtD
Bismuth Subsalicylate—Oedema—Epirubicin—pancreatic cancer	0.000215	0.00156	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—GADD45A—pancreatic cancer	0.000215	0.00346	CbGpPWpGaD
Bismuth Subsalicylate—Infection—Epirubicin—pancreatic cancer	0.000214	0.00155	CcSEcCtD
Bismuth Subsalicylate—TF—SIDS Susceptibility Pathways—TNF—pancreatic cancer	0.000211	0.00341	CbGpPWpGaD
Bismuth Subsalicylate—Dizziness—Docetaxel—pancreatic cancer	0.000211	0.00153	CcSEcCtD
Bismuth Subsalicylate—ALB—Lipid and lipoprotein metabolism—APOE—pancreatic cancer	0.000207	0.00333	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—C-MYB transcription factor network—HES1—pancreatic cancer	0.000206	0.00333	CbGpPWpGaD
Bismuth Subsalicylate—Anorexia—Epirubicin—pancreatic cancer	0.000205	0.00148	CcSEcCtD
Bismuth Subsalicylate—ALB—Vitamin B12 Metabolism—APOE—pancreatic cancer	0.000204	0.00328	CbGpPWpGaD
Bismuth Subsalicylate—Vomiting—Docetaxel—pancreatic cancer	0.000203	0.00147	CcSEcCtD
Bismuth Subsalicylate—ALB—Folate Metabolism—SOD2—pancreatic cancer	0.000202	0.00326	CbGpPWpGaD
Bismuth Subsalicylate—Rash—Docetaxel—pancreatic cancer	0.000201	0.00146	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Docetaxel—pancreatic cancer	0.000201	0.00145	CcSEcCtD
Bismuth Subsalicylate—Confusional state—Doxorubicin—pancreatic cancer	0.000201	0.00145	CcSEcCtD
Bismuth Subsalicylate—Headache—Docetaxel—pancreatic cancer	0.0002	0.00145	CcSEcCtD
Bismuth Subsalicylate—Oedema—Doxorubicin—pancreatic cancer	0.000199	0.00144	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Selenium Micronutrient Network—SOD2—pancreatic cancer	0.000198	0.0032	CbGpPWpGaD
Bismuth Subsalicylate—Infection—Doxorubicin—pancreatic cancer	0.000198	0.00143	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—WT1—pancreatic cancer	0.000192	0.00309	CbGpPWpGaD
Bismuth Subsalicylate—TF—Platelet activation, signaling and aggregation—SRC—pancreatic cancer	0.000192	0.00309	CbGpPWpGaD
Bismuth Subsalicylate—Somnolence—Epirubicin—pancreatic cancer	0.000192	0.00138	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Doxorubicin—pancreatic cancer	0.00019	0.00137	CcSEcCtD
Bismuth Subsalicylate—Nausea—Docetaxel—pancreatic cancer	0.00019	0.00137	CcSEcCtD
Bismuth Subsalicylate—Dyspepsia—Epirubicin—pancreatic cancer	0.00019	0.00137	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Epirubicin—pancreatic cancer	0.000187	0.00135	CcSEcCtD
Bismuth Subsalicylate—ALB—Transmembrane transport of small molecules—FXYD3—pancreatic cancer	0.000187	0.00301	CbGpPWpGaD
Bismuth Subsalicylate—TF—Platelet activation, signaling and aggregation—VEGFA—pancreatic cancer	0.000187	0.00301	CbGpPWpGaD
Bismuth Subsalicylate—Constipation—Epirubicin—pancreatic cancer	0.000184	0.00133	CcSEcCtD
Bismuth Subsalicylate—Pain—Epirubicin—pancreatic cancer	0.000184	0.00133	CcSEcCtD
Bismuth Subsalicylate—TF—Hemostasis—PLAU—pancreatic cancer	0.000181	0.00291	CbGpPWpGaD
Bismuth Subsalicylate—Feeling abnormal—Epirubicin—pancreatic cancer	0.000178	0.00128	CcSEcCtD
Bismuth Subsalicylate—Somnolence—Doxorubicin—pancreatic cancer	0.000177	0.00128	CcSEcCtD
Bismuth Subsalicylate—Dyspepsia—Doxorubicin—pancreatic cancer	0.000176	0.00127	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Doxorubicin—pancreatic cancer	0.000173	0.00125	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—SHH—pancreatic cancer	0.000172	0.00278	CbGpPWpGaD
Bismuth Subsalicylate—TF—Platelet activation, signaling and aggregation—TGFB1—pancreatic cancer	0.000171	0.00276	CbGpPWpGaD
Bismuth Subsalicylate—Urticaria—Epirubicin—pancreatic cancer	0.000171	0.00124	CcSEcCtD
Bismuth Subsalicylate—Constipation—Doxorubicin—pancreatic cancer	0.00017	0.00123	CcSEcCtD
Bismuth Subsalicylate—Pain—Doxorubicin—pancreatic cancer	0.00017	0.00123	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Epirubicin—pancreatic cancer	0.00017	0.00123	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—IAPP—pancreatic cancer	0.00017	0.00274	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—pancreatic cancer	0.00017	0.00274	CbGpPWpGaD
Bismuth Subsalicylate—Feeling abnormal—Doxorubicin—pancreatic cancer	0.000164	0.00119	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CASP3—pancreatic cancer	0.000163	0.00262	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—PIK3CG—pancreatic cancer	0.000161	0.00259	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Selenium Micronutrient Network—SOD2—pancreatic cancer	0.000161	0.00259	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—EGF—pancreatic cancer	0.000159	0.00256	CbGpPWpGaD
Bismuth Subsalicylate—Urticaria—Doxorubicin—pancreatic cancer	0.000158	0.00114	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Doxorubicin—pancreatic cancer	0.000158	0.00114	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Epirubicin—pancreatic cancer	0.000152	0.0011	CcSEcCtD
Bismuth Subsalicylate—ALB—Transmembrane transport of small molecules—SLC29A1—pancreatic cancer	0.000152	0.00246	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Aryl Hydrocarbon Receptor—SRC—pancreatic cancer	0.000151	0.00244	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—EZH2—pancreatic cancer	0.000149	0.0024	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—pancreatic cancer	0.000148	0.00238	CbGpPWpGaD
Bismuth Subsalicylate—Diarrhoea—Epirubicin—pancreatic cancer	0.000147	0.00107	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—GADD45A—pancreatic cancer	0.000146	0.00235	CbGpPWpGaD
Bismuth Subsalicylate—TF—Platelet activation, signaling and aggregation—PIK3CA—pancreatic cancer	0.000146	0.00235	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Aryl Hydrocarbon Receptor—NRAS—pancreatic cancer	0.000146	0.00235	CbGpPWpGaD
Bismuth Subsalicylate—Dizziness—Epirubicin—pancreatic cancer	0.000142	0.00103	CcSEcCtD
Bismuth Subsalicylate—TF—Hemostasis—PIK3CD—pancreatic cancer	0.000141	0.00228	CbGpPWpGaD
Bismuth Subsalicylate—Pruritus—Doxorubicin—pancreatic cancer	0.000141	0.00102	CcSEcCtD
Bismuth Subsalicylate—PTGS1—Selenium Micronutrient Network—PTGS2—pancreatic cancer	0.00014	0.00226	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—pancreatic cancer	0.000139	0.00224	CbGpPWpGaD
Bismuth Subsalicylate—Vomiting—Epirubicin—pancreatic cancer	0.000137	0.00099	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Doxorubicin—pancreatic cancer	0.000136	0.000986	CcSEcCtD
Bismuth Subsalicylate—Rash—Epirubicin—pancreatic cancer	0.000136	0.000982	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Aryl Hydrocarbon Receptor—MYC—pancreatic cancer	0.000136	0.00219	CbGpPWpGaD
Bismuth Subsalicylate—Dermatitis—Epirubicin—pancreatic cancer	0.000136	0.000981	CcSEcCtD
Bismuth Subsalicylate—Headache—Epirubicin—pancreatic cancer	0.000135	0.000976	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Aryl Hydrocarbon Receptor—EGFR—pancreatic cancer	0.000133	0.00214	CbGpPWpGaD
Bismuth Subsalicylate—Dizziness—Doxorubicin—pancreatic cancer	0.000132	0.000953	CcSEcCtD
Bismuth Subsalicylate—Nausea—Epirubicin—pancreatic cancer	0.000128	0.000925	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Doxorubicin—pancreatic cancer	0.000127	0.000916	CcSEcCtD
Bismuth Subsalicylate—ALB—Platelet degranulation—EGF—pancreatic cancer	0.000127	0.00204	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Aryl Hydrocarbon Receptor—TNF—pancreatic cancer	0.000126	0.00204	CbGpPWpGaD
Bismuth Subsalicylate—Rash—Doxorubicin—pancreatic cancer	0.000126	0.000908	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Doxorubicin—pancreatic cancer	0.000126	0.000908	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Aryl Hydrocarbon Receptor—KRAS—pancreatic cancer	0.000125	0.00202	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—STK11—pancreatic cancer	0.000125	0.00202	CbGpPWpGaD
Bismuth Subsalicylate—Headache—Doxorubicin—pancreatic cancer	0.000125	0.000903	CcSEcCtD
Bismuth Subsalicylate—PTGS2—C-MYB transcription factor network—CDKN2A—pancreatic cancer	0.000124	0.00199	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—PIK3CB—pancreatic cancer	0.000123	0.00199	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Response to elevated platelet cytosolic Ca2+—EGF—pancreatic cancer	0.000121	0.00195	CbGpPWpGaD
Bismuth Subsalicylate—TF—Platelet activation, signaling and aggregation—AKT1—pancreatic cancer	0.000119	0.00192	CbGpPWpGaD
Bismuth Subsalicylate—Nausea—Doxorubicin—pancreatic cancer	0.000118	0.000856	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—pancreatic cancer	0.000118	0.00191	CbGpPWpGaD
Bismuth Subsalicylate—ALB—SLC-mediated transmembrane transport—SLC2A2—pancreatic cancer	0.000113	0.00183	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—BRCA2—pancreatic cancer	0.000113	0.00182	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—SMAD4—pancreatic cancer	0.00011	0.00177	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—TYMS—pancreatic cancer	0.000108	0.00173	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—RB1—pancreatic cancer	0.000107	0.00173	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Aryl Hydrocarbon Receptor—HRAS—pancreatic cancer	0.000107	0.00172	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—C-MYB transcription factor network—CCND1—pancreatic cancer	0.000105	0.00169	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—SRC—pancreatic cancer	9.88e-05	0.00159	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—VEGFA—pancreatic cancer	9.62e-05	0.00155	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—NRAS—pancreatic cancer	9.5e-05	0.00153	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Selenium Micronutrient Network—TNF—pancreatic cancer	9.48e-05	0.00153	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Vitamin B12 Metabolism—TNF—pancreatic cancer	9.42e-05	0.00152	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—IFNA5—pancreatic cancer	9.1e-05	0.00147	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Selenium Micronutrient Network—PTGS2—pancreatic cancer	9.02e-05	0.00145	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—C-MYB transcription factor network—NRAS—pancreatic cancer	9e-05	0.00145	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—TGFB1—pancreatic cancer	8.83e-05	0.00142	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—PPP2R5B—pancreatic cancer	8.6e-05	0.00139	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—CXCL8—pancreatic cancer	8.55e-05	0.00138	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—C-MYB transcription factor network—MYC—pancreatic cancer	8.39e-05	0.00135	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—CASP3—pancreatic cancer	8.18e-05	0.00132	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—KRAS—pancreatic cancer	8.18e-05	0.00132	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—NFKBIA—pancreatic cancer	8.16e-05	0.00131	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—CCND1—pancreatic cancer	7.97e-05	0.00128	CbGpPWpGaD
Bismuth Subsalicylate—ALB—FOXA2 and FOXA3 transcription factor networks—AKT1—pancreatic cancer	7.89e-05	0.00127	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—EGF—pancreatic cancer	7.81e-05	0.00126	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—C-MYB transcription factor network—KRAS—pancreatic cancer	7.75e-05	0.00125	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—MMP9—pancreatic cancer	7.73e-05	0.00125	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet degranulation—VEGFA—pancreatic cancer	7.67e-05	0.00124	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Folate Metabolism—TNF—pancreatic cancer	7.66e-05	0.00124	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Selenium Micronutrient Network—TNF—pancreatic cancer	7.53e-05	0.00121	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—PIK3CA—pancreatic cancer	7.52e-05	0.00121	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—PRSS1—pancreatic cancer	7.36e-05	0.00119	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—pancreatic cancer	7.3e-05	0.00118	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—TP53—pancreatic cancer	7.27e-05	0.00117	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet degranulation—TGFB1—pancreatic cancer	7.04e-05	0.00113	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—PRSS1—pancreatic cancer	6.98e-05	0.00112	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—ZNRF3—pancreatic cancer	6.98e-05	0.00112	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—HRAS—pancreatic cancer	6.95e-05	0.00112	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Folate Metabolism—TP53—pancreatic cancer	6.76e-05	0.00109	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—pancreatic cancer	6.7e-05	0.00108	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—C-MYB transcription factor network—HRAS—pancreatic cancer	6.59e-05	0.00106	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—MYC—pancreatic cancer	6.39e-05	0.00103	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—ARG2—pancreatic cancer	6.38e-05	0.00103	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—TGFB1—pancreatic cancer	6.37e-05	0.00103	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—DTX1—pancreatic cancer	6.31e-05	0.00102	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—EGFR—pancreatic cancer	6.25e-05	0.00101	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—AKT1—pancreatic cancer	6.14e-05	0.00099	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Selenium Micronutrient Network—TNF—pancreatic cancer	6.09e-05	0.000981	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—TNF—pancreatic cancer	5.95e-05	0.000959	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—PRSS1—pancreatic cancer	5.84e-05	0.000942	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Transmembrane transport of small molecules—SLC2A2—pancreatic cancer	5.76e-05	0.000928	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—PIK3CG—pancreatic cancer	5.69e-05	0.000917	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—EGF—pancreatic cancer	5.62e-05	0.000906	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—TYMP—pancreatic cancer	5.58e-05	0.000899	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—CASP3—pancreatic cancer	5.57e-05	0.000897	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—pancreatic cancer	5.42e-05	0.000873	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—pancreatic cancer	5.37e-05	0.000865	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—DTX4—pancreatic cancer	5.29e-05	0.000852	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—TP53—pancreatic cancer	5.25e-05	0.000846	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—pancreatic cancer	5.23e-05	0.000843	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—CD44—pancreatic cancer	5.15e-05	0.00083	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—PPP2R5B—pancreatic cancer	5.14e-05	0.000829	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—ARG2—pancreatic cancer	5.07e-05	0.000817	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—PIK3CD—pancreatic cancer	5e-05	0.000806	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—IFNA1—pancreatic cancer	4.99e-05	0.000804	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—HEY2—pancreatic cancer	4.95e-05	0.000798	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—SRC—pancreatic cancer	4.85e-05	0.000782	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—PRSS1—pancreatic cancer	4.73e-05	0.000762	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—pancreatic cancer	4.72e-05	0.000761	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—IFNA2—pancreatic cancer	4.64e-05	0.000748	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	4.6e-05	0.000742	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—HEY1—pancreatic cancer	4.59e-05	0.000739	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—GLP1R—pancreatic cancer	4.5e-05	0.000725	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—TYMP—pancreatic cancer	4.43e-05	0.000714	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—DPYD—pancreatic cancer	4.42e-05	0.000713	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—PIK3CB—pancreatic cancer	4.36e-05	0.000702	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—pancreatic cancer	4.35e-05	0.000701	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—pancreatic cancer	4.34e-05	0.000699	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—pancreatic cancer	4.25e-05	0.000685	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—SLC2A2—pancreatic cancer	4.2e-05	0.000677	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	4.15e-05	0.00067	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—ARG2—pancreatic cancer	4.1e-05	0.000661	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—JAG2—pancreatic cancer	4.07e-05	0.000656	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—pancreatic cancer	4.05e-05	0.000653	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—pancreatic cancer	4.02e-05	0.000647	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	4.01e-05	0.000646	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—MEN1—pancreatic cancer	4.01e-05	0.000646	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—SLC2A2—pancreatic cancer	3.98e-05	0.000641	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—SHH—pancreatic cancer	3.82e-05	0.000616	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—IAPP—pancreatic cancer	3.78e-05	0.000609	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—pancreatic cancer	3.69e-05	0.000595	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	3.65e-05	0.000589	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	3.65e-05	0.000589	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—HSPA1B—pancreatic cancer	3.62e-05	0.000584	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—TYMP—pancreatic cancer	3.58e-05	0.000578	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—GLP1R—pancreatic cancer	3.57e-05	0.000575	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—pancreatic cancer	3.57e-05	0.000575	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—DPYD—pancreatic cancer	3.51e-05	0.000566	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—SRC—pancreatic cancer	3.49e-05	0.000563	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—VEGFA—pancreatic cancer	3.4e-05	0.000548	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—SLC2A2—pancreatic cancer	3.33e-05	0.000537	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	3.3e-05	0.000532	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—PLAU—pancreatic cancer	3.29e-05	0.000531	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—CD44—pancreatic cancer	3.25e-05	0.000524	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—JAG1—pancreatic cancer	3.24e-05	0.000523	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	3.18e-05	0.000513	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	3.18e-05	0.000513	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	3.15e-05	0.000508	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—TGFB1—pancreatic cancer	3.12e-05	0.000503	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—GCG—pancreatic cancer	3.12e-05	0.000502	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—CD44—pancreatic cancer	3.08e-05	0.000497	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—HSPA1A—pancreatic cancer	3.06e-05	0.000493	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—pancreatic cancer	3.01e-05	0.000486	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	2.96e-05	0.000477	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—PIK3CG—pancreatic cancer	2.93e-05	0.000472	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—STK11—pancreatic cancer	2.93e-05	0.000472	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	2.9e-05	0.000467	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—EGF—pancreatic cancer	2.9e-05	0.000467	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—GLP1R—pancreatic cancer	2.89e-05	0.000466	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—DPYD—pancreatic cancer	2.84e-05	0.000458	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	2.75e-05	0.000443	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—SLC2A2—pancreatic cancer	2.7e-05	0.000435	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	2.67e-05	0.00043	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—PIK3CA—pancreatic cancer	2.66e-05	0.000428	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—CD44—pancreatic cancer	2.58e-05	0.000416	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—PIK3CD—pancreatic cancer	2.58e-05	0.000415	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	2.58e-05	0.000415	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	2.53e-05	0.000407	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—TYMS—pancreatic cancer	2.52e-05	0.000406	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—GCG—pancreatic cancer	2.47e-05	0.000399	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—SMAD4—pancreatic cancer	2.43e-05	0.000392	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—HES1—pancreatic cancer	2.38e-05	0.000383	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	2.35e-05	0.000378	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—STK11—pancreatic cancer	2.33e-05	0.000375	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—PIK3CB—pancreatic cancer	2.25e-05	0.000362	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	2.18e-05	0.000352	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—AKT1—pancreatic cancer	2.17e-05	0.00035	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—CD44—pancreatic cancer	2.09e-05	0.000337	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—TERT—pancreatic cancer	2.08e-05	0.000336	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—APOE—pancreatic cancer	2.05e-05	0.00033	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	2.04e-05	0.00033	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	2.03e-05	0.000327	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—GCG—pancreatic cancer	2e-05	0.000323	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—TYMS—pancreatic cancer	2e-05	0.000323	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—HIF1A—pancreatic cancer	1.99e-05	0.000321	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—TSC2—pancreatic cancer	1.99e-05	0.00032	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—APOE—pancreatic cancer	1.94e-05	0.000313	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	1.94e-05	0.000313	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—STK11—pancreatic cancer	1.88e-05	0.000303	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—PIK3CG—pancreatic cancer	1.85e-05	0.000298	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—SRC—pancreatic cancer	1.8e-05	0.00029	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—NOTCH1—pancreatic cancer	1.79e-05	0.000289	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—PPARG—pancreatic cancer	1.79e-05	0.000288	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	1.77e-05	0.000285	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—VEGFA—pancreatic cancer	1.75e-05	0.000283	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—EGF—pancreatic cancer	1.73e-05	0.000279	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—NRAS—pancreatic cancer	1.73e-05	0.000279	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—APOE—pancreatic cancer	1.63e-05	0.000262	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—PIK3CD—pancreatic cancer	1.63e-05	0.000262	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—TYMS—pancreatic cancer	1.62e-05	0.000261	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—TGFB1—pancreatic cancer	1.61e-05	0.000259	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—PIK3CD—pancreatic cancer	1.54e-05	0.000249	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	1.54e-05	0.000248	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—KRAS—pancreatic cancer	1.49e-05	0.00024	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—PIK3CG—pancreatic cancer	1.47e-05	0.000237	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—PIK3CB—pancreatic cancer	1.42e-05	0.000229	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—PPARG—pancreatic cancer	1.42e-05	0.000229	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—PTGS2—pancreatic cancer	1.4e-05	0.000226	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—PIK3CA—pancreatic cancer	1.37e-05	0.000221	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—PIK3CB—pancreatic cancer	1.34e-05	0.000217	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—TP53—pancreatic cancer	1.32e-05	0.000214	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—APOE—pancreatic cancer	1.32e-05	0.000212	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—PIK3CD—pancreatic cancer	1.29e-05	0.000208	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—HRAS—pancreatic cancer	1.27e-05	0.000204	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	1.25e-05	0.000201	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—PTEN—pancreatic cancer	1.23e-05	0.000197	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—CTNNB1—pancreatic cancer	1.19e-05	0.000192	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—PIK3CG—pancreatic cancer	1.19e-05	0.000192	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—PTEN—pancreatic cancer	1.16e-05	0.000187	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—PPARG—pancreatic cancer	1.15e-05	0.000185	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—PIK3CB—pancreatic cancer	1.13e-05	0.000181	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—AKT1—pancreatic cancer	1.12e-05	0.00018	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—SRC—pancreatic cancer	1.08e-05	0.000174	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—PIK3CD—pancreatic cancer	1.04e-05	0.000168	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—STAT3—pancreatic cancer	1.04e-05	0.000167	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—NRAS—pancreatic cancer	1.04e-05	0.000167	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—PTEN—pancreatic cancer	9.73e-06	0.000157	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—MYC—pancreatic cancer	9.65e-06	0.000156	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—TGFB1—pancreatic cancer	9.63e-06	0.000155	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—EGFR—pancreatic cancer	9.44e-06	0.000152	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—PIK3CB—pancreatic cancer	9.11e-06	0.000147	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—PTGS2—pancreatic cancer	9.02e-06	0.000145	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—KRAS—pancreatic cancer	8.92e-06	0.000144	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—PIK3CA—pancreatic cancer	8.64e-06	0.000139	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—PIK3CA—pancreatic cancer	8.19e-06	0.000132	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—PTEN—pancreatic cancer	7.87e-06	0.000127	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—HRAS—pancreatic cancer	7.58e-06	0.000122	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—AKT1—pancreatic cancer	7.06e-06	0.000114	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—PIK3CA—pancreatic cancer	6.86e-06	0.000111	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—AKT1—pancreatic cancer	6.69e-06	0.000108	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—AKT1—pancreatic cancer	5.61e-06	9.04e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—PIK3CA—pancreatic cancer	5.55e-06	8.95e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—AKT1—pancreatic cancer	4.53e-06	7.31e-05	CbGpPWpGaD
